Diamics Supplies Cervical Cancer-Screening System to Beijing Hospital in $22M Deal | GenomeWeb
NEW YORK (GenomeWeb News) — Diamics will supply its molecular-based cancer-diagnostics systems and cervical cancer tools to a Beijing hospital for three years in exchange for at least $22 million, the company said today.
 
Diamics’ C-Map cervical cancer screening system, which is in clinical trials in the US, uses antibodies to identify cell colonies showing dysregulated growth, which could help identify cervical lesions. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.